このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Evaluation Criteria, Diagnostic Criteria, Surgical Indications, and Establishment of Surgical Standards for "Cerebral Tinnitus Syndrome" Caused by Internal Jugular Vein Stenosis.

"Cerebral Tinnitus," also known as "cranial tinnitus," refers to the patient-reported perception of intracranial sounds. It often presents as "Cerebral Tinnitus Syndrome," which includes symptoms such as tinnitus with hearing loss, headaches, a heavy head sensation, blurred vision, neck and shoulder discomfort, sleep disturbances, anxiety, and depression. Due to limited awareness of cerebral tinnitus, patients frequently seek treatment across multiple facilities without success, severely impacting their and their families' lives and work.

Xunming Ji and colleagues have pointed out that cerebral tinnitus results from stenosis of the cerebral or internal jugular veins (IJVS), which impairs cerebral venous outflow and the clearance of metabolic "waste," leading to chronic metabolic damage to brain cells. Currently, studies on the diagnosis and treatment of IJVS-induced cerebral tinnitus, both domestically and internationally, are primarily case reports, lacking systematic evaluation, diagnostic, and treatment standards, which significantly impacts patient outcomes.

Our project team is the first to establish evaluation criteria, diagnostic standards, surgical indications, and surgical standards for "Cerebral Tinnitus Syndrome." In preliminary work, we performed internal jugular vein (IJV) decompression on 32 cerebral tinnitus patients, resulting in an IJV morphological improvement rate of 84.3%, a blood flow improvement rate of 75.0%, and a cerebral tinnitus syndrome improvement rate of 62.5%. To date, we have completed 88 IJV decompression surgeries, making ours the largest clinical center for such cases worldwide. We continue to refine these standards, notably introducing new intraoperative standards for IJV "release" and "high perfusion,".

To validate and further study these standards, this project plans to perform IJV decompression surgery on 107 cerebral tinnitus patients affected by IJVS. We aim to establish a cerebral tinnitus database and develop a cerebral tinnitus evaluation scale to standardize evaluation criteria, diagnostic standards, surgical indications, and surgical standards, ultimately advancing clinical diagnosis and treatment of Cerebral Tinnitus Syndrome

調査の概要

詳細な説明

"Cerebral tinnitus," also known as "cranial tinnitus," is a condition where patients perceive intracranial sounds, often described as complex noises like machinery, thunder, or sirens, and may occur intermittently or persistently. Clinically, cerebral tinnitus is typically not an isolated symptom but manifests as "Cerebral Tinnitus Syndrome." In addition to cerebral tinnitus, patients frequently experience symptoms such as tinnitus with hearing loss, headaches and dizziness, head fullness or heaviness, dry eyes with blurred vision, neck and shoulder discomfort, sleep disturbances, anxiety, depression, and cognitive or memory decline.

A recent study published in the Journal of the American Medical Association: Neurology indicates that approximately 750 million people worldwide suffer from tinnitus. Due to the similarity between the symptoms of tinnitus and cerebral tinnitus, many tinnitus patients also experience cerebral tinnitus, making it difficult to distinguish between these symptoms accurately. Consequently, a substantial portion of the surveyed population may, in fact, be patients with "Cerebral Tinnitus Syndrome."

The fast-paced nature of modern life, coupled with increased stress from work and daily responsibilities, has contributed to the rising incidence of cerebral tinnitus, which has now become a common condition impacting quality of life and overall health in China. Unfortunately, effective treatments for "Cerebral Tinnitus Syndrome" remain unavailable. With limited public awareness about cerebral tinnitus, many patients seek medical help without success; conventional medications yield limited results, and patients often rely on anti-anxiety or antidepressant medications to alleviate symptoms, which severely impacts their and their families' lives and work.

Currently, the etiology of cerebral tinnitus remains unclear. Some studies suggest it may be related to alterations in blood flow within the dural sinuses or internal jugular veins (IJVs) caused by head and neck venous return obstruction or compensatory blood flow in collateral veins. Ji Xunming et al. proposed that cerebral tinnitus could result from stenosis of the cerebral or internal jugular veins, leading to impaired cerebral venous return, inadequate clearance of metabolic waste, and chronic metabolic alterations in brain cells. Specific causes may include cerebral venous thrombosis (CVT), cerebral venous sinus stenosis (CVSS), and internal jugular vein stenosis (IJVS). Unlike CVT and CVSS, IJVS is often caused by external compression, with the transverse process of the atlas and styloid process being primary contributors, affecting 40-70% of cases.

Currently, treatment approaches for cerebral tinnitus are primarily symptom-focused, lacking effective interventions targeting the underlying cause. Medications such as antidepressants and anxiolytics are mainly used to alleviate emotional symptoms, while steroids may temporarily reduce inflammatory responses associated with tinnitus, yet do not address IJVS-induced cerebral tinnitus. Audiotherapy and psychotherapy may improve psychological responses to symptoms but fail to treat the root cause. Surgical interventions may offer symptom relief in some cases with clear etiology; however, there are only a few case reports. Most available treatments are symptomatic rather than causal, underscoring the need for standardized diagnostic and treatment protocols for IJVS-induced cerebral tinnitus.

Systematic research on surgical interventions for IJVS has developed relatively recently. In 2021, Ji Xunming and colleagues summarized recent advancements in IJVS diagnosis and treatment, identifying the upper segment of the internal jugular vein as vulnerable to compression by the atlas transverse process and styloid process. For IJVS patients with distinct bony compression, surgical resection of the compressive bone has been reported to alleviate preoperative symptoms such as headaches, dizziness, and cognitive impairment. Dashti et al. reported on two IJVS patients with craniovertebral junction compression, whose symptoms improved after partial bone resection. Fritch et al. presented a case of IJVS with intracranial hypertension caused by compression from the C1 transverse process, which improved rapidly after resection. Higgins et al. examined 29 styloidectomy surgeries in IJVS patients, finding that of 23 patients undergoing the procedure for the first time without stenting, one achieved complete symptom resolution, four experienced symptom improvement, while the remaining 18 required stenting within two months. Yang et al. reported clinical improvement in 11 of 14 IJVS patients treated with condylar suboccipital lateral approach decompression. From the literature, only limited case studies and small clinical cohorts abroad focus on surgical treatment for IJVS, with no related literature from domestic studies. Additionally, there are no standardized evaluation, diagnostic, or treatment protocols for Cerebral Tinnitus Syndrome caused by IJVS.

Our team is the first globally to establish evaluation criteria, diagnostic standards, surgical indications, and surgical protocols for "Cerebral Tinnitus Syndrome" induced by IJVS. In previous work, we performed internal jugular vein (IJV) decompression on 32 patients with cerebral tinnitus, achieving an IJV morphological improvement rate of 84.3% (27/32), a blood flow improvement rate of 75.0% (24/32), and a cerebral tinnitus syndrome improvement rate of 62.5% (20/32). To date, we have completed 88 minimally invasive surgeries for IJVS-induced cerebral tinnitus, establishing the largest clinical center for these cases worldwide. We continue to refine standards, notably introducing intraoperative IJV "release" and "high perfusion" as new surgical criteria.

To further validate and expand upon these standards, this study plans to perform IJV decompression on 107 patients with IJVS-induced Cerebral Tinnitus Syndrome. Key surgical steps include: (1) standardized bony decompression, (2) soft tissue release, and (3) IJV high perfusion. Enrolled patients will undergo structured evaluation based on our established IJVS-induced Cerebral Tinnitus Syndrome assessment criteria, including "clinical symptom assessment, imaging assessment, and multidisciplinary collaborative evaluation." From these assessments, we will develop more precise diagnostic criteria and clinical classifications. Surgery will be guided by stricter surgical indications to ensure optimal patient selection, and intraoperative validation of the new techniques (standardized bony decompression, soft tissue release, and IJV high perfusion) will be conducted to achieve complete J3 segment decompression. This will set new surgical operation standards, establish a cerebral tinnitus database, create an evaluation scale for cerebral tinnitus, and examine key factors influencing clinical efficacy of IJV decompression. Through this research, we aim to enhance clinical diagnosis and treatment capabilities for IJVS-induced Cerebral Tinnitus Syndrome, relieving patient suffering and improving quality of life.

研究の種類

介入

入学 (推定)

369

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Zhiqiang Hu
  • 電話番号:86+13501378609
  • メールneuro7@163.com

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100038
        • 募集
        • Beijing Shijitan Hospital, Capital Medical University
        • コンタクト:
          • Zhiqiang Hu
          • 電話番号:86+13501378609
          • メールneuro7@163.com

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  1. Age between 18 and 75 years, with no gender restriction.
  2. Presence of one or more symptoms associated with "Cerebral Tinnitus Syndrome," with a duration of at least 3 months.
  3. Following a detailed medical history and comprehensive physical examination, other known causes of cerebral tinnitus are preliminarily excluded, with suspected internal jugular vein stenosis (IJVS) as the cause.
  4. Imaging studies (e.g., jugular ultrasound, cervical venous CT venography (CTV)) show significant stenosis in the internal jugular vein (stenosis degree ≥50%).
  5. The patient has provided informed consent and voluntarily agrees to participate in the study, with a signed informed consent form.

Exclusion Criteria:

  1. Patients with a history of cranial surgery or diagnosed intracranial space-occupying lesions.
  2. Patients with severe cardiac, hepatic, or renal insufficiency, or other systemic diseases.
  3. Patients who have undergone any surgical or interventional procedures affecting jugular venous flow within the last 6 months.
  4. Patients with a history of psychiatric disorders or cognitive impairment who cannot complete study evaluations.
  5. Pregnant or breastfeeding women.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Surgical Intervention Group
Internal Jugular Vein Decompression is a surgical procedure designed to relieve stenosis or external compression of the internal jugular vein, restore normal cerebral venous outflow, and alleviate symptoms related to chronic venous congestion such as pulsatile tinnitus (tinnitus cerebri), positional headache, and visual disturbances.It can be performed via open surgical decompression (releasing surrounding soft tissue/bony compression) or endovascular intervention (balloon angioplasty/stenting) to treat significant jugular vein stenosis refractory to medical management.
This surgical procedure is performed with the patient in the lateral decubitus position (affected side up), under electrophysiological monitoring of the sternocleidomastoid and trapezius muscles. A 3-4 cm straight incision is made below the mastoid tip, and the atlas transverse process is exposed via careful dissection along the anterior border of the sternocleidomastoid muscle while preserving the cervical branch of the facial nerve. Under endoscopy and microscopy, the anterolateral portion of the transverse process is thoroughly drilled using diamond burrs (4 mm and 2 mm) according to preoperative CTV measurements. After bone resection, the carotid sheath is opened to expose the internal jugular vein (IJV), and perivascular soft tissues are fully released over a width of more than 2 cm to decompress the entire J3 segment of the IJV. Subsequently, the systolic blood pressure is elevated by at least 20% above baseline and maintained for 30 minutes to achieve IJV hyperperfusion and prom

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Cerebral tinnitus improvement rate at 3 months postoperatively
時間枠:3 months postoperatively

Assessed by VAS score (0-10). Improvement defined as:

Marked improvement: ≥30% reduction in VAS Mild improvement: 10%-30% reduction No obvious change: 0%-10% reduction Aggravation: increased VAS

3 months postoperatively

二次結果の測定

結果測定
メジャーの説明
時間枠
Cerebral tinnitus improvement rate at 12 months postoperatively
時間枠:12 months postoperatively
Assessed by VAS score (0-10) with the same improvement criteria.
12 months postoperatively
Improvement rate of other clinical symptoms at 3 and 12 months postoperatively
時間枠:3 and 12 months postoperatively
Assessed by VAS score (0-10) with the same improvement criteria.
3 and 12 months postoperatively
Morphological improvement of the internal jugular vein (IJV) postoperatively
時間枠:3 and 12 months postoperatively
Assessed by CTV; improvement defined by percentage increase in IJV diameter at decompressed segment.
3 and 12 months postoperatively
Blood flow recovery of IJV postoperatively
時間枠:3 and 12 months postoperatively
Assessed by Doppler ultrasound; improvement defined by percentage increase in blood flow velocity at IJV J3 segment
3 and 12 months postoperatively
Safety outcomes
時間枠:3 and 12 months postoperatively
Incidence of adverse events (AEs) and serious adverse events (SAEs), including intraoperative vascular/nerve injury, wound infection, neck-shoulder discomfort, and limited neck movement.
3 and 12 months postoperatively

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年5月7日

一次修了 (推定)

2029年12月30日

研究の完了 (推定)

2030年12月30日

試験登録日

最初に提出

2026年4月24日

QC基準を満たした最初の提出物

2026年4月24日

最初の投稿 (実際)

2026年5月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月1日

QC基準を満たした最後の更新が送信されました

2026年4月24日

最終確認日

2025年5月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • BeijingShijitanHCapitalMU sjwk
  • ZLRK202512 (その他の助成金/資金番号:Beijing Municipal Hospital Management Center)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Baseline demographic data (age, gender, body mass index, medical history). Preoperative and postoperative VAS scores for tinnitus cerebri and other clinical symptoms at 3 and 12 months.

Imaging measurements: IJV diameter on CTV at the decompressed segment pre- and postoperatively.

Hemodynamic data: blood flow velocity of the IJV J3 segment measured by Doppler ultrasound.

Safety data: occurrence, time, and severity of adverse events and serious adverse events.

Data will be shared after de-identification, without exposing participant privacy or protected health information.

IPD 共有時間枠

The IPD and related supporting information will be made available **starting from the date of study completion**, and will remain accessible for **5 years after the end of the study**.

IPD 共有アクセス基準

Clinical Study Report (CSR)

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する